Bassam Nasreddine Karout

Originator Medical Innovations

Nutraceuticals for unmet chronic needs, specifically for Pharma licensing.

Founder and managing director of

I create nutraceuticals licensable to pharmaceutical companies

Prescribed by Doctors

For Chronic Applications

Supported by Clinical Studies

2O+ years' experience in medical industry

From Med Rep to DB to R&D.

25+ Markets

Licensed to pharma manufacturers and to pharma distributors

Uppsala University Researcher

Researcher at Department of Medical Sciences; Gastroenterology/Hepatalogy

Sample Publications

Read the Full Article

Read the Full Article

Read the Full Article

I create nutraceuticals licensable to pharmaceutical companies

Prescribed by Doctors

For Chronic Applications

Supported by Clinical Studies

2O+ years' experience in medical industry

From Med Rep to DB to R&D.

25+ Markets

Licensed to pharma manufacturers and to pharma distributors

Uppsala University Researcher

Researcher at Department of Medical Sciences; Gastroenterology/Hepatalogy

Sample Publications

Read the Full Article

Read the Full Article

Read the Full Article

I create nutraceuticals licensable to pharmaceutical companies

Prescribed by Doctors

For Chronic Applications

Supported by Clinical Studies

2O+ years' experience in medical industry

From Med Rep to DB to R&D.

25+ Markets

Licensed to pharma manufacturers and to pharma distributors

Uppsala University Researcher

Researcher at Department of Medical Sciences; Gastroenterology/Hepatalogy

Sample Publications

Read the Full Article

Read the Full Article

Read the Full Article

Proven Commercial Impact

Innovation is only valuable when it reaches the patient. This portfolio demonstrates a repeatable track record of turning clinical concepts into licensed market leaders worldwide.

Current Development

Ventrazym

An originator product establishing credibility and validation at record speed.

Current Development

Ventrazym

An originator product establishing credibility and validation at record speed.

Previous co-development

Enzymax Forte

Licensed to five market leaders in 26+ countries.

Previous co-development

Retixoft

A originator diabetic retinopathy product, balanced with earlier diagnosis tools developed for the ophthalmologists.

Previous co-development

Enzymax Forte

Licensed to five market leaders in 26+ countries.

Previous co-development

Retixoft

A originator diabetic retinopathy product, balanced with earlier diagnosis tools developed for the ophthalmologists.

The approach

Proven Commercial Impact

Rather than operating isolated projects, I built an integrated medical innovation ecosystem that spans research, development, clinical validation, regulatory execution, and international deployment as a harmonious flowing process.

Innovation is only valuable when it reaches the patient. This portfolio demonstrates a repeatable track record of turning clinical concepts into licensed market leaders worldwide.

Current Development

Ventrazym

An originator product establishing credibility and validation at record speed.

Previous co-development

Enzymax Forte

Licensed to five market leaders in 26+ countries.

Previous co-development

Retixoft

A originator diabetic retinopathy product, balanced with earlier diagnosis tools developed for the ophthalmologists.

The approach

Rather than operating isolated projects, I built an integrated medical innovation ecosystem that spans research, development, clinical validation, regulatory execution, and international deployment as a harmonious flowing process.

Originator pricing strategy

Product is alone on the market or highly differentiated.

Originator pricing strategy

Product is alone on the market or highly differentiated.

Strong Science positioning

Involve your KOLs for natural endorsement.

Studies in multiple university hospitals.

Involve patient advocacy group for organic patient endorsement.

Strong Science positioning

Involve your KOLs for natural endorsement.

Studies in multiple university hospitals.

Involve patient advocacy group for organic patient endorsement.

Smooth Pharma licensing

KOLs do not need to change prescribing behaviour.

Pharmaceutical companies do not need to adjust promotional model (medical reps visiting KOLs).

Chronic applications for a large market segment.

The Ecosystem

What exists today is not a portfolio of ventures, but a functioning operating system for medical innovation each component serving a precise role in the same logic:

R&D since 2013

A Cambridge- based product creation engine focused on reducing unnecessary suffering in chronic conditions.

Research in diabetes since 2023

A structured Nordic academic research network addressing overlooked digestive complications in diabetes.

Patient advocacy since 2025

A collaboration with patient associations and advocacy groups across Europe.

IBD since 2009

Licensing to pharmaceutical companies internationally. Full circle: Registrations in importing health authorities, launch and post sales support. Ongoing deals since 2009.

The Ecosystem

What exists today is not a portfolio of ventures, but a functioning operating system for medical innovation each component serving a precise role in the same logic:

R&D since 2013

A Cambridge- based product creation engine focused on reducing unnecessary suffering in chronic conditions.

Tangible Example: how innovation works here.

Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.
Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.
Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.
Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.

Tangible Example: how innovation works here.

Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.
Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.
Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.
Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.
Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.
Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.
Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.
Step 1: Identify Clinical Friction
We pinpoint recurring patient and/or KOL complaints that cause unnecessary damage or pain.
Ongoing Example
Severe shortages of pancreatin with devastating impact on chronic patients.
Low effectiveness (only active in the intestine), very low impact on painful symptoms.
Step 2: The Milltons Solution
We design a targeted concept to resolve or enhance the situation.
Ongoing Example
Design a product with no supply bottle neck on API and easy to scale production.
Increase effectiveness. Start activity in the stomach, maintain it throughout the digestive system.
Step 3: The Research Network
We engage leading physician involved in research in reputed European university hospitals to fine-tune and validates the concept before development.
Ongoing Example
Gastroenterologists and Internal Medicine physicians help us fine tune the formulation to optimise the treatment.
Step 4: Milltons Product Creation
Our research network conducts initial studies at record speed in multiple universities. We start selecting a medical board of director.
Ongoing Example
Study in Uppsala University GastroLabs
Study in Athens Medical School
Invitation for the medical network to join the board
VentraZym is Born
Superior to legacy technology, the product launches with non-generic pricing. We secured three studies in the first three months, while network physicians transitioned to the medical board.
Differentiated and superior to Pancreatin 25K
Two physicians representing top 1% of medical scientists
Three studies in three universities, three more planned for 2026
Step 6: Patient advocacy Associations
We involve patient advocacy groups for patient-initiated studies to drive adoption.
Ongoing Example
Provide trainings for associations members using our network.
Provide free diagnostics using our medical network.
Generate patient-initiated studies.
Step 7: Yesfal Global Scaling
License to international pharmaceutical leaders rapidly. We specialise in international regulatory frameworks, selecting pre-registered contract manufacturers to shorten registration and launch timelines. The documentation is designed to be international-friendly from scratch.
Ongoing Example
Build the dossier to be international Pharma licensing friendly.

Focus Areas

While the model is transferable, current work naturally concentrates on areas where quality of life can be improved immediately, including:

Diabetes

Gastroenterology

CNS

Ophthalmology

The unifying theme is simple: resolving unnecessary suffering where existing approaches fall short.

An Open System

This ecosystem continues to evolve through collaboration with clinicians, researchers, patient groups, and partners who recognise that meaningful medical innovation does not need to be slow to be rigorous.

If what you are building touches an unmet need and requires clinical credibility, speed, and real-world adoption, then let’s have a conversation.

This ecosystem continues to evolve through collaboration with clinicians, researchers, patient groups, and partners who recognise that meaningful medical innovation does not need to be slow to be rigorous.

If what you are building touches an unmet need and requires clinical credibility, speed, and real-world adoption, then let’s have a conversation.

Speaker Presenting at Conference with Audience

Bassam Nasreddine Karout

Originator Medical Innovations

Nutraceuticals for unmet chronic needs, specifically for Pharma licensing.

I create nutraceuticals licensable to pharmaceutical companies

Prescribed by Doctors

For Chronic Applications

Supported by Clinical Studies

2O+ years' experience in medical industry

25+ Markets

Uppsala University Researcher

Sample Publications

I create nutraceuticals licensable to pharmaceutical companies

Prescribed by Doctors

For Chronic Applications

Supported by Clinical Studies

2O+ years' experience in medical industry

25+ Markets

Uppsala University Researcher

Sample Publications

I create nutraceuticals licensable to pharmaceutical companies

Prescribed by Doctors

For Chronic Applications

Supported by Clinical Studies

2O+ years' experience in medical industry

25+ Markets

Uppsala University Researcher

Sample Publications

Proven Commercial Impact

Innovation is only valuable when it reaches the patient. This portfolio demonstrates a repeatable track record of turning clinical concepts into licensed market leaders worldwide.

Ventrazym

Ventrazym

Enzymax Forte

Retixoft

Enzymax Forte

Retixoft

The approach

Proven Commercial Impact

Rather than operating isolated projects, I built an integrated medical innovation ecosystem that spans research, development, clinical validation, regulatory execution, and international deployment as a harmonious flowing process.

Ventrazym

Enzymax Forte

Retixoft

The approach

Originator pricing strategy

Originator pricing strategy

Strong Science positioning

Strong Science positioning

Smooth Pharma licensing

The Ecosystem

What exists today is not a portfolio of ventures, but a functioning operating system for medical innovation each component serving a precise role in the same logic:

The Ecosystem

Tangible Example: how innovation works here.

Step 1: Identify Clinical Friction

Step 2: The Milltons Solution

Step 3: The Research Network

Step 4: Milltons Product Creation

VentraZym is Born

Step 6: Patient advocacy Associations

Step 7: Yesfal Global Scaling

Step 1: Identify Clinical Friction

Step 2: The Milltons Solution

Step 3: The Research Network

Step 4: Milltons Product Creation

VentraZym is Born

Step 6: Patient advocacy Associations

Step 7: Yesfal Global Scaling

Step 1: Identify Clinical Friction

Step 2: The Milltons Solution

Step 3: The Research Network

Step 4: Milltons Product Creation

VentraZym is Born

Step 6: Patient advocacy Associations

Step 7: Yesfal Global Scaling

Step 1: Identify Clinical Friction

Step 2: The Milltons Solution

Step 3: The Research Network

Step 4: Milltons Product Creation

VentraZym is Born

Step 6: Patient advocacy Associations

Step 7: Yesfal Global Scaling

Tangible Example: how innovation works here.